Conference
A phase 2 study of GTI-2040 plus docetaxel and prednisone as 1st line treatment in hormone-refractory prostate cancer (HRPC).
Authors
Sridhar SS; Canil CM; Hotte SJ; Chi KN; Ernst S; Pond GR; Dick C; Zwiebel JA; Moore MJ
Volume
11
Pagination
pp. 8974S-8974S
Publisher
AMER ASSOC CANCER RESEARCH
Publication Date
December 15, 2005
Name of conference
AACR/NCI/EORTC International Conference on Molecular Targets and Cancer Therapeutics
Conference place
Philadelphia, PA
Conference start date
November 14, 2005
Conference end date
November 18, 2005
Conference proceedings
CLINICAL CANCER RESEARCH
Issue
24
ISSN
1078-0432